Generic placeholder image

Current Rheumatology Reviews

Editor-in-Chief

ISSN (Print): 1573-3971
ISSN (Online): 1875-6360

Systemic Sclerosis: From Pathogenesis Towards Targeted Immunotherapies

Author(s): Lazaros I. Sakkas, Ian C. Chikanza and Chris D. Platsoucas

Volume 8, Issue 1, 2012

Page: [45 - 55] Pages: 11

DOI: 10.2174/157339712801318920

Price: $65

Abstract

Systemic sclerosis (SSc), a chronic disease with widespread collagen deposition, has three pathogenetic facets: immune activation, microvasculopathy and fibroblast activation. Immune activation and microvasculopathy occur very early in the disease process, and inflammatory infiltrates in the skin are restricted in early-phase disease. There is good evidence that fibroblast activation with collagen production may be triggered by the immune system. In early-phase disease, we slowly move from general immunosuppression to therapeutically targeting specific molecules involved in immune activation, such as T cell-directed targets, B cell-directed targets, cytokine targets, and tyrosine kinases targets.

Keywords: B cell, fibroblast, immune activation, immunotherapy, systemic sclerosis, targeted therapy, T cell


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy